77 related articles for article (PubMed ID: 21114487)
41. Reply to "Comments on: Acute aerobic exercise-conditioned serum reduces colon cancer cell proliferation in vitro through interleukin-6-induced regulation of DNA damage".
Orange ST; Jordan AR; Odell A; Kavanagh O; Hicks KM; Todryk S; Saxton JM
Int J Cancer; 2022 Nov; 151(9):1642-1643. PubMed ID: 35716144
[No Abstract] [Full Text] [Related]
42. Interleukin-6 signaling pathway in targeted therapy for cancer.
Guo Y; Xu F; Lu T; Duan Z; Zhang Z
Cancer Treat Rev; 2012 Nov; 38(7):904-10. PubMed ID: 22651903
[TBL] [Abstract][Full Text] [Related]
43. Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis.
Dadgar N; Sherry C; Zimmerman J; Park H; Lewis C; Donnenberg A; Zaidi AH; Fan Y; Xiao K; Bartlett D; Donnenberg V; Wagner PL
J Transl Med; 2024 Apr; 22(1):402. PubMed ID: 38689325
[TBL] [Abstract][Full Text] [Related]
44. Tocilizumab Exerts Anti-Tumor Effects on Colorectal Carcinoma Cell Xenografts Corresponding to Expression Levels of Interleukin-6 Receptor.
Chung YC; Chen SJ; Huang CC; Liu WC; Lai MT; Kao TY; Yang WS; Yang CH; Hsu CP; Chang JF
Pharmaceuticals (Basel); 2024 Jan; 17(1):. PubMed ID: 38256960
[TBL] [Abstract][Full Text] [Related]
45. IL-6/JAK2-dependent G6PD phosphorylation promotes nucleotide synthesis and supports tumor growth.
Qiu X; Ye H; Li X; Li D; Jiang L; Liu R; Zhao Z; He D
Mol Metab; 2023 Dec; 78():101836. PubMed ID: 37949355
[TBL] [Abstract][Full Text] [Related]
46. PRRX1 promotes colorectal cancer stemness and chemoresistance via the JAK2/STAT3 axis by targeting IL-6.
Zhong L; Tan W; Yang Q; Zou Z; Zhou R; Huang Y; Qiu Z; Zheng K; Huang Z
J Gastrointest Oncol; 2022 Dec; 13(6):2989-3008. PubMed ID: 36636075
[TBL] [Abstract][Full Text] [Related]
47. The association between circulating levels of vitamin D and inflammatory markers in the first 2 years after colorectal cancer diagnosis.
Wesselink E; Balvers M; Bours MJL; de Wilt JHW; Witkamp RF; van Baar H; Geijsen AJMR; van Halteren H; Keulen ETP; Kok DE; Kouwenhoven EA; van den Ouweland J; van Zutphen M; Weijenberg MP; Kampman E; van Duijnhoven FJB
Therap Adv Gastroenterol; 2020; 13():1756284820923922. PubMed ID: 32547638
[TBL] [Abstract][Full Text] [Related]
48. Effects of Anti-Cytokine Antibodies on Gut Barrier Function.
Liu F; Lee SA; Riordan SM; Zhang L; Zhu L
Mediators Inflamm; 2019; 2019():7028253. PubMed ID: 31780866
[TBL] [Abstract][Full Text] [Related]
49. Current evidence for vitamin D in intestinal function and disease.
Hassanshahi M; Anderson PH; Sylvester CL; Stringer AM
Exp Biol Med (Maywood); 2019 Sep; 244(12):1040-1052. PubMed ID: 31366237
[TBL] [Abstract][Full Text] [Related]
50. PIAS1 inhibited the metastasis of gastric cancer cell by epithelial-mesenchymal transition regulation within the inflammatory microenvironment.
Wang X; Wang L; Xu Y; Zhang G; Wu Y; Chen P
Oncol Lett; 2018 Mar; 15(3):3828-3837. PubMed ID: 29556278
[TBL] [Abstract][Full Text] [Related]
51. Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling.
Zhang X; Hu F; Li G; Li G; Yang X; Liu L; Zhang R; Zhang B; Feng Y
Cell Death Dis; 2018 Jan; 9(2):25. PubMed ID: 29348540
[TBL] [Abstract][Full Text] [Related]
52. Estrogen receptor α in cancer associated fibroblasts suppresses prostate cancer invasion via reducing CCL5, IL6 and macrophage infiltration in the tumor microenvironment.
Yeh CR; Slavin S; Da J; Hsu I; Luo J; Xiao GQ; Ding J; Chou FJ; Yeh S
Mol Cancer; 2016 Jan; 15():7. PubMed ID: 26790618
[TBL] [Abstract][Full Text] [Related]
53. Colorectal cancer-promoting activity of the senescent peritoneal mesothelium.
Mikuła-Pietrasik J; Sosińska P; Maksin K; Kucińska MG; Piotrowska H; Murias M; Woźniak A; Szpurek D; Książek K
Oncotarget; 2015 Oct; 6(30):29178-95. PubMed ID: 26284488
[TBL] [Abstract][Full Text] [Related]
54. Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells.
Kim NH; Kim SK; Kim DS; Zhang D; Park JA; Yi H; Kim JS; Shin HC
Oncol Lett; 2015 May; 9(5):2283-2288. PubMed ID: 26137057
[TBL] [Abstract][Full Text] [Related]
55. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction.
Nagasaki T; Hara M; Nakanishi H; Takahashi H; Sato M; Takeyama H
Br J Cancer; 2014 Jan; 110(2):469-78. PubMed ID: 24346288
[TBL] [Abstract][Full Text] [Related]
56. Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma.
Gordziel C; Bratsch J; Moriggl R; Knösel T; Friedrich K
Br J Cancer; 2013 Jul; 109(1):138-46. PubMed ID: 23756862
[TBL] [Abstract][Full Text] [Related]
57. Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies.
Ataie-Kachoie P; Morris DL; Pourgholami MH
PLoS One; 2013; 8(4):e60817. PubMed ID: 23593315
[TBL] [Abstract][Full Text] [Related]
58. The absence of Nrf2 enhances NF-κB-dependent inflammation following scratch injury in mouse primary cultured astrocytes.
Pan H; Wang H; Wang X; Zhu L; Mao L
Mediators Inflamm; 2012; 2012():217580. PubMed ID: 22529521
[TBL] [Abstract][Full Text] [Related]
59. Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with α5β1 integrin in glioma.
Kesanakurti D; Chetty C; Dinh DH; Gujrati M; Rao JS
Oncogene; 2013 Jan; 32(3):327-40. PubMed ID: 22349830
[TBL] [Abstract][Full Text] [Related]
60. The colorectal tumor microenvironment: the next decade.
Beauchemin N
Cancer Microenviron; 2011 Aug; 4(2):181-5. PubMed ID: 21735168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
